adra2da Antibody

What applications can ADRA2A antibodies be reliably used for in research?

ADRA2A (Alpha-2A Adrenergic Receptor) antibodies have been validated for multiple applications in scientific research. Based on comprehensive analysis of commercially available antibodies, the following applications have demonstrated consistent reliability:

When selecting an ADRA2A antibody, prioritize those with validation data in your specific application and species of interest. Most commercial antibodies have been tested with human, mouse, and rat samples, with PC-12 cells and brain tissue frequently used as positive controls .

What is the optimal fixation protocol for ADRA2A immunohistochemistry?

The optimal fixation protocol for ADRA2A detection in tissue samples requires careful consideration of fixative type, duration, and antigen retrieval methods:

For formalin-fixed paraffin-embedded (FFPE) tissues:

• 4% paraformaldehyde fixation for 24-48 hours is recommended

• Antigen retrieval methods significantly impact ADRA2A detection

• TE buffer (pH 9.0) has demonstrated superior retrieval compared to citrate buffer

• For ADRA2A in pancreatic cancer research, overnight incubation at 4°C with rabbit monoclonal anti-ADRA2A antibody (dilution 1:200) has been reported with successful results

Signal amplification can be achieved using the Dako envision+ system-HRP labeled polymer anti-rabbit antibody, with color development using 3,3'-diaminobenzidine (DAB) . When evaluating staining, utilize both intensity and prevalence scoring systems, with intensity scores ranging from 0-3 (negative to strong) and prevalence scores ranging from 0-4 (<10% to >80% positive cells) .

What are the optimal conditions for Western blot detection of ADRA2A?

When performing Western blot analysis for ADRA2A detection, researchers should consider the following technical parameters to obtain optimal results:

Sample Preparation:

• For membrane proteins like ADRA2A, specialized lysis buffers containing mild detergents (0.5-1% NP-40 or Triton X-100) are recommended

• Complete protease inhibitor cocktails should be included to prevent degradation

• Kidney membrane preparations from mouse have been successfully used as positive controls

Electrophoresis and Transfer:

• ADRA2A has a calculated molecular weight of approximately 49 kDa

• Observed molecular weight typically ranges between 45-51 kDa depending on glycosylation status

• Use 8-10% SDS-PAGE gels for optimal resolution

• Transfer proteins to PVDF membranes rather than nitrocellulose for better protein retention

Antibody Conditions:

• Primary antibody dilutions: 1:200-1:1000 in blocking buffer containing 5% BSA

• Overnight incubation at 4°C yields better results than shorter incubations

• For secondary detection, HRP-conjugated anti-rabbit antibodies (1:5000-1:10000) have demonstrated high sensitivity and specificity

Researchers should note that PC-12 cells consistently show reliable ADRA2A expression and serve as an excellent positive control for validating Western blot protocols .

How can I troubleshoot weak or non-specific bands when detecting ADRA2A?

ADRA2A detection by Western blot may present several technical challenges. Here are methodological approaches to address common issues:

Weak Signal:

• Increase primary antibody concentration (reduce dilution)

• Extend primary antibody incubation time to overnight at 4°C

• Use enhanced chemiluminescence (ECL) substrates with higher sensitivity

• Increase protein loading (50-100 μg total protein per lane)

• Verify sample preparation protocol includes appropriate detergents for membrane protein extraction

Non-specific Bands:

• Use 5% BSA instead of milk for blocking and antibody dilution

• Increase washing time and volume (5 washes, 10 minutes each with TBST)

• Pre-adsorb antibody with non-specific proteins

• Reduce secondary antibody concentration

• Confirm antibody specificity using knockout/knockdown controls or blocking peptides

High Background:

• Use freshly prepared blocking buffer

• Ensure thorough membrane washing between steps

• Filter all buffers before use to remove particulates

• Use highly purified antibody preparations (affinity-purified antibodies show superior performance)

When troubleshooting Western blots, it's advisable to test multiple ADRA2A antibodies targeting different epitopes, as epitope accessibility can vary between experimental conditions .

How can ADRA2A antibodies be used to investigate pancreatic cancer molecular subtypes?

Recent research has identified ADRA2A as a suppressor of the basal-like/squamous pancreatic ductal adenocarcinoma (PDAC) subtype. Integrating ADRA2A antibody applications in pancreatic cancer research requires sophisticated methodological approaches:

Immunohistochemical Analysis of PDAC Subtypes:

• ADRA2A antibody (rabbit monoclonal, 1:200 dilution) can effectively differentiate between classical/progenitor and basal-like/squamous PDAC subtypes

• Scoring systems combining intensity (0-3) and prevalence (0-4) provide quantitative assessment of ADRA2A expression

• Reduced ADRA2A expression correlates with higher pathological grade, lymph node metastasis, and advanced disease stage

Transcriptome-Proteome Correlation:

• Perform immunohistochemistry on tissue microarrays from PDAC patient cohorts

• Correlate ADRA2A protein expression with RNA-seq data from matched samples

• Integrate with patient clinicopathological features and survival data

• Validate findings using in vitro models with ADRA2A transgene expression or ADRA2A agonist treatment

This integrated approach has revealed that heightened ADRA2A expression induces transcriptome and metabolome characteristics of the classical/progenitor subtype with decreased disease aggressiveness in PDAC patients. ADRA2A IHC scoring has potential as a prognostic biomarker and therapeutic target in pancreatic cancer .

What are the methodological considerations for co-localization studies of ADRA2A with other G protein-coupled receptors?

Co-localization studies examining ADRA2A interactions with other G protein-coupled receptors require careful experimental design and specialized antibody selection:

Antibody Selection for Multiplexing:

• Choose ADRA2A antibodies raised in different host species (rabbit, goat) to enable dual or triple labeling

• Verify non-overlapping epitopes when using multiple antibodies against ADRA2A

• Confirm antibody specificity using appropriate controls (knockout tissues, blocking peptides)

Immunofluorescence Protocol Optimization:

• Sequential immunostaining may be required to prevent cross-reactivity

• Use Tyramide Signal Amplification (TSA) to enhance detection sensitivity

• Employ spectral unmixing to resolve overlapping fluorophore signals

• Consider super-resolution microscopy techniques for detailed co-localization analysis

• Use the recommended dilution ranges: IF (1:100-1:500) for optimal signal-to-noise ratio

Quantitative Co-localization Analysis:

• Calculate Pearson's correlation coefficient, Manders' overlap coefficient, or intensity correlation quotient

• Employ automated image analysis software with consistent thresholding algorithms

• Compare co-localization in different tissue regions or cell compartments

• Validate findings with proximity ligation assays or FRET-based approaches

These methodological considerations enable rigorous evaluation of ADRA2A interactions with other GPCRs in various experimental contexts, providing insights into receptor heteromerization and functional interactions .

How do I validate ADRA2A antibody cross-reactivity across different species?

Validating ADRA2A antibody cross-reactivity across species requires systematic experimental design and appropriate controls:

Sequence Alignment Analysis:

• Compare the immunogen sequence with target species' ADRA2A sequence

• Many ADRA2A antibodies use highly conserved epitopes, enhancing cross-species reactivity

• For example, the immunogen sequence R(218)IYQIAKRRTRVPPSRRG(235) from the 3rd intracellular loop is completely conserved between human, mouse, rat, and porcine ADRA2A

Experimental Validation Strategy:

• Test antibody on positive control tissues from target species (brain, kidney)

• Include negative controls (non-expressing tissues or knockout samples)

• Verify expected molecular weight across species (approximately 45-51 kDa)

• Compare staining patterns with published literature on ADRA2A distribution

• Consider using multiple antibodies targeting different epitopes for confirmation

Cross-Reactivity Table for Common ADRA2A Antibodies:

When testing novel species, researchers should always perform extensive validation and consider the innovator award programs offered by some antibody manufacturers for establishing new cross-reactivity data .

How can ADRA2A antibodies be used to investigate G-protein coupled signaling pathways?

Investigating ADRA2A-mediated G-protein coupled signaling pathways requires specialized experimental approaches using antibodies targeting both the receptor and downstream signaling components:

Phospho-Specific Antibody Selection:

• ADRA2A couples primarily to the inhibitory G-alpha subunit (Gi)

• Measure decreased cAMP levels upon ADRA2A activation

• Use phospho-specific antibodies against downstream targets (pERK1/2, pAkt)

• Design time-course experiments (5, 15, 30, 60 min) following ADRA2A agonist stimulation

Co-Immunoprecipitation Protocol:

• Utilize ADRA2A antibodies (1:100 dilution) for immunoprecipitation from membrane fractions

• Analyze co-precipitated proteins by Western blot using antibodies against G proteins

• Include appropriate controls (IgG control, blocking peptide)

• Consider mild detergents (0.5% NP-40 or digitonin) to preserve protein-protein interactions

Functional Analysis using Phosphorylation Status:

• Compare basal and stimulated phosphorylation states in ADRA2A-expressing vs. control cells

• Use selective agonists and antagonists to confirm pathway specificity

• Analyze phosphorylation patterns in subcellular fractions (membrane, cytosolic, nuclear)

• Integrate findings with physiological responses through calcium imaging or electrophysiology

ADRA2A inhibits the flow of sympathetic nerves in the central nervous system and plays major roles in sedation, anxiolysis, and antinociception. These signaling studies can illuminate the molecular mechanisms underlying these physiological functions .

What methodological approaches should be used to study ADRA2A internalization and trafficking?

Studying ADRA2A internalization and trafficking dynamics requires specialized techniques that combine antibody-based detection with advanced imaging methodologies:

Live-Cell Imaging Protocol:

• Use N-terminal tagged ADRA2A constructs (GFP, mCherry) to monitor trafficking in real-time

• Supplement with antibody feeding assays using extracellular epitope-targeted ADRA2A antibodies

• Apply agonist stimulation (selective alpha-2A agonists) at physiologically relevant concentrations

• Capture images at defined intervals (30 sec, 2 min, 5 min, 15 min, 30 min)

• Quantify receptor internalization using automated image analysis algorithms

Subcellular Fractionation and Western Blot Analysis:

• Separate membrane, cytosolic, and endosomal fractions using differential centrifugation

• Analyze ADRA2A distribution using Western blot (1:500 antibody dilution)

• Include markers for different cellular compartments (Na+/K+ ATPase, EEA1, Rab7)

• Compare constitutive vs. agonist-induced trafficking patterns

Immunofluorescence Co-localization with Endocytic Markers:

• Fix cells at various time points after agonist treatment

• Co-stain with ADRA2A antibody (1:200 dilution) and markers for:

  • Early endosomes (EEA1)

  • Recycling endosomes (Rab11)

  • Late endosomes/lysosomes (LAMP1)

• Quantify co-localization coefficients to determine trafficking pathways

These methodological approaches provide comprehensive insights into the spatiotemporal dynamics of ADRA2A following activation, which is critical for understanding receptor desensitization and resensitization mechanisms in various physiological contexts .